Vivani Medical Business Summary

Vivani Medical, Inc. (VANI) is a clinical-stage biopharmaceutical company that generates value through the development of ultra-long-acting, miniaturized subdermal implants powered by its proprietary NanoPortal™ technology. The company’s business model is currently focused on the research and clinical progression of its two primary segments: the Biopharm Division, which develops six-month GLP-1 implants (NPM-139 and NPM-133) for obesity and type 2 diabetes, and the Neuromodulation Division, which operates through its subsidiary Cortigent to develop brain-implantable neuroprosthetics like the Orion visual cortical prosthesis. While currently pre-revenue, Vivani’s monetization strategy targets future product commercialization, strategic licensing, and milestone-based partnerships. Within the medical equipment and biotech landscape, Vivani competes with firms such as Perspective Therapeutics (CATX), RxSight (RXST), and Delcath Systems (DCTH), distinguishing itself by offering a high-adherence, twice-yearly dosing alternative to the dominant weekly injectable and oral therapies in the metabolic health market. The company is led by Co-founder and CEO Dr. Adam Mendelsohn, Ph.D., a bioengineering specialist from the UCSF/UC Berkeley Joint Program whose foundational research in drug delivery systems underpins the NanoPortal platform. The executive suite includes CFO Anthony Baldor, a biotech finance veteran who joined in 2025 from 4D Molecular Therapeutics, and COO Truc Le, who manages the company’s manufacturing and operational scaling. Vivani’s strategic and financial backing is anchored by Chairman Gregg Williams, the CEO of Williams International and a major investor who has led multiple recent capital raises. The Board of Directors further benefits from the pedigree of industry leaders like Daniel Bradbury, the former CEO of Amylin Pharmaceuticals, and Dean Baker, Ph.D., the founding director of the Alfred E. Mann Institute for Biomedical Engineering, providing deep expertise in both metabolic disease commercialization and medical device innovation.